可诱导共刺激分子配体在系统性红斑狼疮血清中水平及临床意义

萧健萍; 周强; 张森; 贺文涛; 王雪荣; 潘海峰; 王德光

doi:10.16462/j.cnki.zhjbkz.2016.10.008

可诱导共刺激分子配体在系统性红斑狼疮血清中水平及临床意义

doi: 10.16462/j.cnki.zhjbkz.2016.10.008

1. 安徽医科大学第二附属医院肾脏内科, 安徽合肥 230601;
2. 安徽医科大学第一附属医院检验科, 安徽合肥 230032;
3. 安徽医科大学公共卫生学院流行病与卫生统计系, 安徽合肥 230032

基金项目:

中国博士后科学基金（2012M511399）；安徽省自然科学基金（1508085MH148）；安徽省博士后科学基金（9101019202）

详细信息

作者简介:
萧健萍(1990-),女,安徽宿州人,在读硕士研究生。主要研究方向:系统性红斑狼疮。

中图分类号: R593.24
计量
- 文章访问数: 322
- HTML全文浏览量: 61
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2016-05-19
- 修回日期: 2016-08-27

Serum levels and clinical significance of soluble ICOSL in patients with systemic lupus erythematosus

1. Department of Nephrology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China;
2. Department of clinical laboratory, the First Affiliated Hospital of Anhui Medical University, Hefei 230032, China;
3. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei 230032, China

摘要

摘要: 目的探讨可诱导共刺激分子配体（inducible costimulator molecule ligand，ICOSL）在系统性红斑狼疮（systemic lupus erythematosus，SLE）患者血清表达水平变化，并分析其临床意义。方法纳入2015年3月1日~2015年8月31日安徽医科大学第一附属医院、第二附属医院的风湿科和肾脏科住院治疗的34例活动性SLE、15例非活动性SLE患者和33例年龄、性别相匹配的健康志愿者，酶联免疫吸附试验（enzyme-linked immunosorbent assay，ELISA）法检测血清标本可溶性ICOSL（sICOSL）水平。结果与健康对照组相比，SLE、狼疮肾炎（lupus nephritis，LN）、活动组血清sICOSL水平降低（P₁=0.004；P₂=0.008；P₃=0.003）；但血清sICOSL水平与SLE疾病活动度、anti-dsDNA滴度、补体C3、补体C4、血沉、24小时尿蛋白、血肌酐、尿素氮均无相关性（均有P>0.05），并且实验室指标阳性组与阴性组sICOSL的血清水平差异均无统计学意义（均有P>0.05）。此外，糖皮质激素或者免疫抑制剂的应用并未对血清sICOSL水平产生影响（t=-0.69，P=0.495）。结论 SLE患者血清ICOSL表达水平降低，提示其可能参与了SLE的发生、发展，但其具体机制尚未明确，需要进一步研究。
- 红斑狼疮,系统性 /
- 狼疮肾炎 /
- 血清
Abstract: Objective To investigate the serum levels of soluble inducible costimulator molecules ligand (ICOSL) in patients with systemic lupus erythematosus (SLE). Methods Serum levels of soluble ICOSL (Sicosl) were measured by enzyme linked immunosorbent assay (ELISA) using plasma samples from 49 SLE patients with or without active lupus and 33 healthy subjects. Results The levels of sICOSL in patients with SLE, lupus nephritis (LN) or active SLE groups were lower than those in healthy controls (P₁=0.004; P₂=0.008;P₃=0.003). However, we did not find any correlations between the concentration of sICOSL and disease activity or clinical indicators (anti-dsDNA titer, C3, C4, ESR, Scr, mTP, BUN) (all P>0.05), and laboratory indexes in positive groups and negative groups did not show difference (all P>0.05). Moreover, the application of corticosteroids or immunosuppressants did not affect the concentration of the sICOSL in SLE patients (t=-0.69, P=0.495). Conclusions Understanding the role of ICOSL in the occurrence and development of SLE may allow us to develop a promising therapeutic strategy for SLE.
- Lupus erythematosus, systemic /
- Lupus nephritis /
- Serum

HTML全文

参考文献(23)

温鹏飞,王晓松,张敏,等. IL-6基因单核苷酸多态性与系统性红斑狼疮的相关性研究[J]. 中华疾病控制杂志, 2014,18(4):277-280.

李若洁,叶冬青. 系统性红斑狼疮的全基因组关联研究进展[J]. 中华疾病控制杂志, 2011,15(7):614-618.

Sharpe AH. Mechanisms of costimulation[J]. Immunol Rev, 2009,229(1):5-11.

Nurieva RI, Mai XM, Forbush K, et al. B7h is required for T cell activation, differentiation, and effector function[J]. Proc Natl Acad Sci U S A, 2003,100(24):14163-14168.

Her M, Kim D, Oh M, et al. Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus[J]. Lupus, 2009,18(6): 501-507.

Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus[J]. J Allergy Clin Immunol, 2011,127(2): 303-312.

Iwai H, Abe M, Hirose S, et al. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis[J]. J Immunol, 2003,171(6):2848-2854.

Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1982,25(11):1271-1277.

Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE[J]. Arthritis Rheum, 1992,35(6): 630-640.

de Haij S, Woltman AM, Trouw LA, et al. Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1[J]. Kidney Int, 2005,68(5):2091-2102.

Ahearne MJ, Willimott S, Pinon L, et al. Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia[J]. Br J Haematol, 2013,162(3):360-370.

Fos C, Salles A, Lang V, et al. ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse[J]. J Immunol, 2008,181(3):1969-1977.

Yoshinaga SK, Zhang M, Pistillo J, et al. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS[J]. Int Immunol, 2000,12(10):1439-1447.

Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity[J]. Nat Med, 2002,8(9):1024-1032.

Gao X, Zhao L, Wang S, et al. Enhanced inducible costimulator ligand (ICOS-L) expression on dendritic cells in interleukin-10 deficiency and its impact on T-cell subsets in respiratory tract infection[J]. Mol Med, 2013,19:346-356.

Froidure A, Vandenplas O, D'Alpaos V, et al. Defects in Plasmacytoid Dendritic Cell Expression of Inducible Costimulator Ligand and IFN-alpha Are Associated in Asthma with Disease Persistence[J]. Am J Respir Crit Care Med, 2015,192(3):392-395.

Maazi H, Patel N, Sankaranarayanan I, et al. ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity[J]. Immunity, 2015,42(3):538-551.

Yanaba K, Asano Y, Noda S, et al. Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis[J]. Arch Dermatol Res, 2013,305(1):17-23.

Wang F, Yan T, Chen L, et al. Involvement of inducible costimulator ligand (ICOSL) expression in thyroid tissue in hyperthyroidism of Graves' disease patients[J]. J Clin Immunol, 2012,32(6):1253-1261.

Hamel KM, Cao Y, Olalekan SA, et al. B cell-specific expression of inducible costimulator ligand is necessary for the induction of arthritis in mice[J]. Arthritis Rheumatol, 2014,66(1): 60-67.

Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy[J]. Cancer Res, 2011,71(16):5445-5454.

Nelson MH, Kundimi S, Bowers JS, et al. The inducible costimulator augments Tc17 cell responses to self and tumor tissue[J]. J Immunol, 2015,194(4):1737-1747.

Rottman JB, Smith T, Tonra JR, et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE[J]. Nat Immunol, 2001,2(7):605-611.

施引文献

资源附件(0)

访问统计